1. A signal synthesis circuit comprising:
a first gain adjusting unit configured to receive luma signals from a video signal source and adjust gains of the luma signals;
a delay unit coupled to the first gain adjusting unit, the delay unit configured to delay phases of the luma signals output by the first gain adjusting unit, wherein the delay unit comprises a plurality of resonance oscillation units coupled in series; and
a second gain adjusting unit coupled to the delay unit, the second gain adjusting unit configured to receive chroma signals from the video signal source and adjust gains of the chroma signals so that the phase delayed luma signals output by the delay unit and the chroma signals output by the second gain adjusting unit are synthesized into composite video broadcast signals (CVBS).
2. The signal synthesis circuit of claim 1, further comprising a direct current (DC) isolation unit, wherein the DC isolation unit is configured to filter out DC interferences from the CVBS.
3. The signal synthesis circuit of claim 2, wherein the DC isolation unit comprises a capacitor, a first end of the capacitor is coupled to a node between the delay unit and the second gain adjusting unit, and a second end of the capacitor is coupled to a tuner.
4. The signal synthesis circuit of claim 1, wherein the first gain adjusting unit comprises a resistor, a first end of the resistor is coupled to the video signal source and the delay unit, and a second end of the resistor is grounded.
5. (canceled)
6. The signal synthesis circuit of claim 1, wherein the delay unit comprises:
a first capacitor with a first end coupled to the first gain adjusting unit and a second
a second capacitor coupled to the first capacitor in parallel;
a first inductor with a first end coupled to a node between the first capacitor and the first gain adjusting unit;
a third capacitor with a first end coupled to a second end of the first inductor and a second end grounded;
a fourth capacitor coupled to the third capacitor in parallel;
a second inductor with a first end coupled to a node between the first inductor and the third capacitor and a second end coupled to the second gain adjusting unit;
a fifth capacitor with a first end coupled to a node between the second inductor and the second gain adjusting unit and a second end grounded; and
a sixth capacitor coupled to the fifth capacitor in parallel.
7. The signal synthesis circuit of claim 1, wherein the second gain adjusting unit comprises:
a first resistor with a first end coupled to the video signal source and a second end coupled to the delay unit; and
a second resistor with a first end coupled to a node between the first resistor and the delay unit and a second end grounded.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A wound healing composition comprising isolated living dermal fibroblast cells having a wound healing phenotype, characterized in that:
(i) the cells of the composition exhibit, at less than 14 days, a 2.08 to 48,200-fold higher level of expression of apolipoprotein D (ApoD); a 694 to 662,000-fold higher level of expression of matrix metalloprotease 2 (MMP2); a 33.7 to 43,300-fold higher level of expression of collagen 3a1 (Coll3a1); and a 20.2 to 121,000-fold higher level of expression of smooth muscle actin (SMA) relative to the expression level of Ribosomal protein L32 (RPL32); or
(ii) 75-99% of the cells of the composition have a banding pattern of polymerase chain reaction (PCR) products resulting from differential display identical or similar to that shown in FIG. 4 or FIG. 5 for nucleic acid expression in fibrin,
wherein the dermal fibroblast cells are comprised within a fibrin support matrix formed by thrombin-mediated polymerization of a fibrinogen and said dermal fibroblasts followed by incubation of said fibrin support matrix at about 37\xb0 C. for about 16-24 hours after formation of said matrix, and
wherein said composition has a shelf-life of at least 7 and up to 28 days, when stored at about 2\xb0 to 8\xb0 C.
2. The wound healing composition of claim 1, in which the matrix is non-pyrogenic andor sterile.
3. The wound healing composition of claim 1, in which the matrix is solid or semi-solid.
4. The wound healing composition of claim 1, in which the cells are mammalian.
5. The wound healing composition of claim 1, in which the cells substantially exclude keratinocytes.
6. The wound healing composition of claim 1, in which the cells exhibit, at less than 14 days, a 360-fold higher mean level of expression of ApoD; a 102,000-fold higher mean level of expression of MMP2; a 800 to 4370-fold higher mean level of expression of Coll3a1; or a 14,100-fold mean higher level of expression of SMA relative to the level of expression of RPL32.
7. The wound healing composition of claim 1, in which the cells are suspended substantially uniformly within the matrix.
8. The wound healing composition of claim 1, in which the matrix has a protein concentration in the range of about 3 to 12 mg.ml\u22121.
9. The wound healing composition of claim 1, in which the cells are human.
10. The wound healing composition of claim 1, in which fibroblasts comprise between about 90% to 100% of the cells of said composition.
11. The wound healing composition of claim 1, in which the cells are not proliferating or not senescent.
12. The wound healing composition of claim 1, further comprising a protease inhibitor.
13. The wound healing composition of claim 12, in which the protease inhibitor is aprotinin or tranexamic acid.
14. The wound healing composition of claim 1, in which the composition has a thickness of approximately 8 mm or less.
15. The wound healing composition of claim 14, in which the composition has a thickness of approximately 5 mm or less.
16. The wound healing composition of claim 1, comprising about 450 to 2500 cells per mm2.
17. The wound healing composition of claim 1, in which the composition is single-layered.
18. The wound healing composition of claim 1, in which the composition is packaged in a container suitable for transporting the composition, storing the composition, or topically applying the composition to a skin surface.
19. The wound healing composition of claim 18, in which the container comprises a flexible pouch consisting of two sheets of impermeable flexible material peripherally sealed to provide a means of containment for the composition, the pouch comprising a first internal surface to which the composition is adherent at a level of adhesion more than between the composition and a second internal surface of the pouch but less than that between the composition and the skin surface, such that in use the pouch may be opened by parting the sheets and the composition conveniently manipulated and directly applied to the skin surface without further requirement for the composition to be touched directly by any other means prior to application.
20. The wound healing composition of claim 1, wherein said wound healing composition is a topical composition.
21. The wound healing composition of claim 1, wherein 90-99% of the cells of the composition have a banding pattern of polymerase chain reaction (PCR) products resulting from differential display identical or similar to that shown in FIG. 4 or FIG. 5 for nucleic acid expression in fibrin.